Which country is the drug produced in and its original drug information?

Biktarvy (Biktarvy) is a three-in-one anti-HIV drug developed and produced by the American biopharmaceutical company Gilead Sciences. Gilead Headquartered in Foster City, California, USA, it is a world-renowned innovative pharmaceutical company focusing on the research and development of viral diseases and liver diseases. Biktarvy As its original product, it integrates a variety of active ingredients, simplifies the treatment plan, improves patient compliance and quality of life, and has become an important choice for first-line treatment of HIV internationally.

Biktarvy ’s three active ingredients include bictegravir (Bictegravir), emtricitabine (Emtricitabine) and tenofovir alafenamide, TAF). Bictegravir is an integrase inhibitor that can prevent viral DNA from integrating into the host cell genome; emtricitabine and TAF are nucleoside reverse transcriptase inhibitors that inhibit viral replication. The three are combined into one tablet, which can be taken once a day, greatly simplifying the medication regimen while maintaining high antiviral activity and reducing the incidence of drug resistance.

Regarding the origin of the original drug, Biktarvy is mainly formulated and packaged in North America, and some of the packaging is marked as originating in Canada. This shows that Gilead has concentrated its drug production, quality control and packaging processes in North America to ensure stable drug quality and consistent production standards. As an original drug, Biktarvy is protected by patent and sold in brand form globally. There are no comparable generic drugs widely used in the international market.

In general, Biktarvy is an innovative original anti-HIV drug launched by Gilead Sciences . It integrates three antiviral ingredients into one tablet, simplifying the treatment plan and improving compliance. Its production and packaging strictly follow North American quality standards to ensure the safety and effectiveness of the drug. The original research identity and brand ensure its core position in global HIV treatment, making it the first-line medication option preferred by patients and clinicians, and at the same time providing HIVtreatment offers long-term, safe and highly effective management options.

Reference:https://reference.medscape.com/